Related Experiment Video
Updated: May 24, 2025

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules
Kaiming Li1,2, Yu Q Yap1,2, Donia M Moujalled1,2
1Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Abstract:
Defective apoptosis mediated by B cell lymphoma 2 antagonist/killer (BAK) or B cell lymphoma 2-associated X protein (BAX) underlies various pathologies including autoimmune and degenerative conditions. On mitochondria, voltage-dependent anion channel 2 (VDAC2) interacts with BAK and BAX through a common interface to inhibit BAK or to facilitate BAX apoptotic activity. We identified a small molecule (WEHI-3773) that inhibits interaction between VDAC2 and BAK or BAX revealing contrasting effects on their apoptotic activity. WEHI-3773 inhibits apoptosis mediated by BAX by blocking VDAC2-mediated BAX recruitment to mitochondria. Conversely, WEHI-3773 promotes BAK-mediated apoptosis by limiting inhibitory sequestration by VDAC2. In cells expressing both pro-apoptotic proteins, apoptosis promotion by WEHI-3773 dominates, because activated BAK activates BAX through a feed-forward mechanism. Loss of BAX drives resistance to the BCL-2 inhibitor venetoclax in some leukemias. WEHI-3773 overcomes this resistance by promoting BAK-mediated killing. This work highlights the coordination of BAX and BAK apoptotic activity through interaction with VDAC2 that may be targeted therapeutically.
Insights
A novel molecule, WEHI-3773, modulates apoptosis by targeting the interaction between VDAC2 and pro-apoptotic proteins BAK and BAX. This drug promotes cell death in certain leukemias, offering a new therapeutic avenue.
Area of Science:
- Cellular biology
- Molecular medicine
- Biochemistry
Background:
- Defective apoptosis involving B cell lymphoma 2 antagonist/killer (BAK) and B cell lymphoma 2-associated X protein (BAX) contributes to various diseases.
- Voltage-dependent anion channel 2 (VDAC2) regulates BAK and BAX activity at the mitochondria.
Purpose of the Study:
- To identify and characterize a small molecule that modulates VDAC2 interactions with BAK and BAX.
- To investigate the therapeutic potential of this molecule in overcoming resistance to apoptosis inhibitors.
Main Methods:
- Small molecule screening to identify VDAC2-BAK/BAX interaction inhibitors.
- Cell-based assays to assess apoptosis induction.
- Mitochondrial recruitment assays for BAK and BAX.
- Evaluation of drug resistance models in leukemia.
Main Results:
- WEHI-3773 inhibits VDAC2-BAX interaction, reducing BAX-mediated apoptosis.
- WEHI-3773 promotes BAK-mediated apoptosis by disrupting VDAC2-BAK sequestration.
- The molecule induces apoptosis in cells co-expressing BAK and BAX, driven by BAK.
- WEHI-3773 overcomes venetoclax resistance in BAX-deficient leukemias by enhancing BAK activity.
Conclusions:
- VDAC2 plays a critical role in coordinating BAK and BAX apoptotic functions.
- WEHI-3773 differentially regulates BAK and BAX, promoting apoptosis through a BAK-dependent feed-forward loop.
- Targeting the VDAC2-BAK/BAX interaction with WEHI-3773 presents a promising strategy for treating pathologies associated with defective apoptosis and drug resistance.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Caspases
Apoptosis
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Regulation of the Unfolded Protein Response

